Current Atherosclerosis Reports

, Volume 7, Issue 3, pp 211–212 | Cite as

Clinical trials report

  • Richard T. Lee


  1. 1.
    Wong J, Patel RA, Kowey PR: The clinical use of angiotensin-converting enzyme inhibitors. Prog Cardiovasc Dis 2004, 47:116–130.PubMedCrossRefGoogle Scholar
  2. 2.
    Braunwald E, Domanski MJ, Fowler SE, et al.; PEACE Trial Investigators: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004, 351:2058–2068.PubMedCrossRefGoogle Scholar
  3. 3.
    The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145–153.CrossRefGoogle Scholar
  4. 4.
    Fox KM: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362:782–788.PubMedCrossRefGoogle Scholar
  5. 5.
    Pitt B: ACE inhibitors for patients with vascular disease without left ventricular dysfunction—may they rest in PEACE? N Engl J Med 2004, 351:2115–2117.PubMedCrossRefGoogle Scholar
  6. 6.
    Nickenig G, Harrison DG: The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part 1: oxidative stress and atherogenesis. Circulation 2002, 105:393–396.PubMedCrossRefGoogle Scholar
  7. 7.
    Daugherty A, Cassis L: Angiotensin II-mediated development of vascular diseases. Trends Cardiovasc Med 2004, 14:117–120.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Richard T. Lee

There are no affiliations available

Personalised recommendations